CA2135201A1 - Vaccin universel contre le coronavirus - Google Patents

Vaccin universel contre le coronavirus

Info

Publication number
CA2135201A1
CA2135201A1 CA002135201A CA2135201A CA2135201A1 CA 2135201 A1 CA2135201 A1 CA 2135201A1 CA 002135201 A CA002135201 A CA 002135201A CA 2135201 A CA2135201 A CA 2135201A CA 2135201 A1 CA2135201 A1 CA 2135201A1
Authority
CA
Canada
Prior art keywords
ala
leu
gln
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002135201A
Other languages
English (en)
Inventor
Timothy J. Miller
Sharon Klepfer
Albert Paul Reed
Elaine V. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2135201A1 publication Critical patent/CA2135201A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002135201A 1992-05-08 1993-05-07 Vaccin universel contre le coronavirus Abandoned CA2135201A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88217192A 1992-05-08 1992-05-08
US07/882,171 1992-05-08

Publications (1)

Publication Number Publication Date
CA2135201A1 true CA2135201A1 (fr) 1993-11-25

Family

ID=25380027

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002135201A Abandoned CA2135201A1 (fr) 1992-05-08 1993-05-07 Vaccin universel contre le coronavirus
CA002134898A Abandoned CA2134898A1 (fr) 1992-05-08 1993-05-07 Compositions et methodes de vaccination contre les coronavirus

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002134898A Abandoned CA2134898A1 (fr) 1992-05-08 1993-05-07 Compositions et methodes de vaccination contre les coronavirus

Country Status (5)

Country Link
EP (2) EP0640096A4 (fr)
JP (2) JPH08501931A (fr)
AU (2) AU678971B2 (fr)
CA (2) CA2135201A1 (fr)
WO (2) WO1993023421A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034298A (en) * 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5612487A (en) * 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
CA2135201A1 (fr) * 1992-05-08 1993-11-25 Timothy J. Miller Vaccin universel contre le coronavirus
EP0640098B1 (fr) * 1992-05-08 2002-10-09 Pfizer Inc. Gene s du coronavirus canin et ses applications
AU721367B2 (en) * 1993-02-26 2000-06-29 Wyeth Holdings Corporation Canine coronavirus vaccine from feline enteric coronavirus
EP0612532A3 (fr) * 1993-02-26 1998-02-04 Solvay Animal Health, Inc. Vaccin contre le coronavirus canin à partir de coronavirus entérique félin
GB2316681B (en) * 1993-09-16 1998-04-15 Dimminaco Ag Sa Ltd Antigenically active proteins/polypeptides and coronavirus vaccines containing the same
FR2724385B1 (fr) * 1994-08-29 1996-12-13 Rhone Merieux Vaccin de la peritonite infectieuse feline.
WO1997010347A1 (fr) * 1995-09-15 1997-03-20 Howard John A Cassettes d'expression et procedes d'administration de vaccins veterinaires
WO1998027433A1 (fr) * 1996-12-18 1998-06-25 Engene Biotechnologies, Inc Diagnostic specifique des anticorps contre le virus de la peritonite infectieuse feline
AU1408499A (en) * 1997-11-14 1999-06-07 Thomas P. Brown Compositions and methods to prevent turkey enteritis
WO2001009290A2 (fr) * 1999-07-30 2001-02-08 Laboratorio Avi-Mex, S.A. De C.V. Serotype du virus de bronchite infectieuse aviaire
FR2828405B1 (fr) * 2001-08-09 2005-06-24 Virbac Sa Vaccin anti-coronavirus
WO2005010034A1 (fr) * 2003-07-21 2005-02-03 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Fragments solubles de la glycoproteine de spicule sras-cov
US7605135B2 (en) * 2003-11-10 2009-10-20 The University Of Hong Kong Baicalin as a treatment for SARS infection
ITMI20111182A1 (it) * 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
WO2015143335A1 (fr) * 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Méthodes et compositions pour protéines spike de coronavirus chimère
CN113248576A (zh) * 2020-02-12 2021-08-13 北京科兴中维生物技术有限公司 一种针对冠状病毒的核酸疫苗及其制备方法
WO2022020815A1 (fr) * 2020-07-24 2022-01-27 Soligenix, Inc. Compositions d'anticorps/d'adjuvants et méthodes de génération de réponse immunitaire contre les coronavirus
CN113072626B (zh) * 2021-04-25 2023-05-05 龙岩学院 一种猫冠状病毒s重组蛋白及其制备方法
CN113238048B (zh) * 2021-05-11 2024-03-15 抗码(苏州)生物科技有限公司 一种诊断标志物及其在区分新冠病毒感染和新冠病毒灭活疫苗接种中的应用
CN114057894B (zh) * 2021-06-18 2022-08-05 国药中生生物技术研究院有限公司 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
CN114478716B (zh) * 2021-12-28 2024-05-28 梅州市人民医院(梅州市医学科学院) 一种多肽组合及其在新型冠状病毒抗体检测中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63123385A (ja) * 1986-09-05 1988-05-27 デュファル・インテルナチオナル・レセールフ・ベー・ヴェー 新規抗原的活性蛋白質およびぺプチド、並びにネコ科感染性腹膜炎ウイルスワクチン
CA2005291C (fr) * 1988-12-30 1999-01-26 Beverly Dale Instruments de diagnostic du virus de la peritonite infectieuse des felins
EP0489033B1 (fr) * 1989-08-22 1994-10-19 Veterinary Infectious Disease Organization Polypeptides de coronavirus bovins et vaccins contre ce virus
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
CA2135201A1 (fr) * 1992-05-08 1993-11-25 Timothy J. Miller Vaccin universel contre le coronavirus
EP0640098B1 (fr) * 1992-05-08 2002-10-09 Pfizer Inc. Gene s du coronavirus canin et ses applications

Also Published As

Publication number Publication date
JPH08501931A (ja) 1996-03-05
EP0640097A1 (fr) 1995-03-01
WO1993023422A1 (fr) 1993-11-25
AU4240493A (en) 1993-12-13
AU4241093A (en) 1993-12-13
WO1993023421A1 (fr) 1993-11-25
AU678970B2 (en) 1997-06-19
EP0640096A1 (fr) 1995-03-01
JPH07508176A (ja) 1995-09-14
AU678971B2 (en) 1997-06-19
EP0640097A4 (fr) 1997-01-15
EP0640096A4 (fr) 1997-01-15
CA2134898A1 (fr) 1993-11-25

Similar Documents

Publication Publication Date Title
CA2135201A1 (fr) Vaccin universel contre le coronavirus
US6616930B2 (en) Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation method
KR102482994B1 (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
EP1525313B1 (fr) Proteine a pointes du coronavirus respiratoire canin (crcv), polymerase et hemagglutinine/esterase correspondantes
AU2014230822B2 (en) Heat-stable Respiratory Syncytial Virus prefusion F protein oligomers and their use in immunological compositions
EP4103228A1 (fr) Vaccin à base d'acide nucléique contre le coronavirus sars-cov-2
US4920213A (en) Method and compositions useful in preventing equine influenza
JP2004313196A (ja) コロナウイルスに対するワクチン接種用組成物および方法
KR100889423B1 (ko) Prrs 백신으로서의 돼지 생식기 호흡기 증후군바이러스 융합 단백질
US4631191A (en) Methods and compositions useful in preventing equine influenza
EP3541419B1 (fr) Composition immunogène pour l'infection par le coronavirus mers
AU732254B2 (en) A human cytomegalovirus combined antigen and its use
KR102116320B1 (ko) 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도
WO1993015763A1 (fr) Polypeptides de vaccination
RU2691302C1 (ru) Иммуногенная композиция на основе рекомбинантных псевдоаденовирусных частиц, а также на основе белковых антигенов и способ получения иммуногенной композиции
CZ292283B6 (cs) Izolovaná kódová sekvence DNA, vektor, hostitelská buňka, protein, farmaceutický prostředek a vakcína
Viaplana et al. Antigenicity of VP60 structural proteinof rabbit haemorrhagic disease virus
KR20230091094A (ko) 융합 단백질 및 백신
TWI412588B (zh) 重組病毒蛋白及顆粒
US20020127245A1 (en) Canine coronavirus S gene and uses therefor
WO1994006468A1 (fr) Compositions de vaccin contre le virus de la griffe, obtenues par recombinaison
KR20220040423A (ko) 재조합 단백질을 포함하는 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
CA2246802C (fr) Antigene combine a un cytomegalovirus humain et son utilisation
KR20230132816A (ko) 복제-능력 있는 아데노바이러스 타입 4 sars-cov-2백신 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued